AstraZeneca Cuts Sales Reps By Reducing PDI Contract; Will Others Follow?

AstraZeneca's decision to reduce the number of contract sales reps may be an early indicator of an industry trend in 2005

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet